Frequency, clinical presentation, and outcomes of drug-induced liver injury after liver transplantation
Authors:
- Stepan SemberaSSStepan Sembera
- Jayant A. TalwalkarJTJayant A. Talwalkar
- Eileen J. HayEHEileen J. Hay
Open Access
- 5 March 2012
- journal article
- research article
- Published by Wolters Kluwer Health in Liver Transplantation
- Vol. 18 (7) , 803-810
Abstract
Drug-induced liver injury (DILI) is increasingly being recognized as a common cause of acute hepatitis. The clinical impact of DILI after liver transplantation (LT) is not known. The aim of this study was to describe the frequency, clinical presentation, and outcomes of DILI in LT recipients. LT recipients with possible DILI were identified with electronic pathology records and clinical note database retrieval tools. Diagnostic criteria were applied to identify cases of DILI. Twenty-nine of 1689 LT recipients (1.7%) were identified with DILI. The mean age was 52 years, and 52% were women. The major indications for LT were primary sclerosing cholangitis (28%), cholangiocarcinoma (14%), and hepatocellular carcinoma (14%). The severity of DILI was mild or moderate in 92% of the cases. Nausea or diarrhea (31%), jaundice (24%), and pruritus (10%) were the most common symptoms at the time of diagnosis. The mean biochemistry values were as follows: alanine aminotransferase, 204 ± 263 U/L; aspartate aminotransferase, 108 ± 237 U/L; alkaline phosphatase, 469 ± 689 U/L; and total bilirubin, 1.9 ± 10.3 mg/dL. The median duration of medication use until the diagnosis of DILI was 57 days, and the major agent classes were antibiotics (48%), immunosuppressive agents (14%), and antihyperlipidemic drugs (7%). Trimethoprim-sulfamethoxazole was the most common implicated agent (n = 11). Serum liver enzymes improved within a median time of 34 days (range = 5–246 days) after drug withdrawal. Hepatic retransplantation or death did not occur. Among the 50 cases with possible DILI explained by other causes, 13 individuals (26%) had no alternative diagnosis despite histological findings compatible with DILI. In conclusion, DILI is a rare yet underrecognized event among LT recipients. The majority of cases are not clinically severe, and they resolve after drug cessation without hepatic retransplantation or death. Liver Transpl, 2012. © 2012 AASLD.Keywords
This publication has 28 references indexed in Scilit:
- Metabolic syndrome in liver transplant recipientsLiver Transplantation, 2010
- Standardization of nomenclature and causality assessment in drug‐induced liver injuryHepatology, 2010
- Evolution of Causes and Risk Factors for Mortality Post‐Liver Transplant: Results of the NIDDK Long‐Term Follow‐Up StudyAmerican Journal of Transplantation, 2010
- Causes, Clinical Features, and Outcomes From a Prospective Study of Drug-Induced Liver Injury in the United StatesGastroenterology, 2008
- Vascular Complications After Orthotopic Liver Transplantation After Neoadjuvant Therapy for Hilar CholangiocarcinomaLiver Transplantation, 2007
- Long-term survival and impact of ursodeoxycholic acid treatment for recurrent primary biliary cirrhosis after liver transplantationLiver Transplantation, 2007
- Drug-induced liver injury: Summary of a single topic clinical research conferenceHepatology, 2006
- Drug-Induced Liver Injury: An Analysis of 461 Incidences Submitted to the Spanish Registry Over a 10-Year PeriodGastroenterology, 2005
- Nodular regenerative hyperplasia of the liver graft after liver transplantationHepatology, 1994
- Etiopathogenesis and prognosis of centrilobular necrosis in hepatic graftsJournal of Hepatology, 1994